{"id":"bms-986489","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the activity of interleukin-1 beta (IL-1β), a cytokine involved in the inflammatory response. This action is expected to reduce inflammation and potentially treat various inflammatory diseases.","oneSentence":"BMS-986489 is an anti-inflammatory agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:19:32.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT06646276","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-25","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":530},{"nctId":"NCT06773910","phase":"PHASE2","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-03-11","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":250},{"nctId":"NCT06799286","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-07","conditions":"Small Cell Lung Carcinoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BMS-986489","genericName":"BMS-986489","companyName":"SCRI Development Innovations, LLC","companyId":"scri-development-innovations-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986489 is an anti-inflammatory agent. Used for Treatment of systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}